Anticancer Potential of Hesperidin against HEp-2 Laryngeal Carcinoma Cell Line in Comparison to Doxorubicin

Résumé

Abstract Background Doxorubicin (DOX) is widely used in therapy of many carcinoma types. Unfortunately, it is not sufficiently effective in many cases and increasing the dosage of it is limited due to systemic toxicity. An important strategy to minimize the toxic effects of the above cited drug is to use co-adjuvant. A citrus flavonoid hesperidin (Hesp) has emerged as promising anticancer natural product and proved to be potent antioxidant agent. It inhibits cancer cell proliferation by inducing apoptosis and cell cycle arrest. In this context, the objective of this study was to investigate anticarcinogenic effects of Hesp in comparison with DOX against HEp-2 laryngeal carcinoma cell line. Methods Five groups of HEp-2 cell line were included, two groups were subjected to Hesp and the other two groups were subjected to DOX, which was used as a reference drug, in addition to a control untreated group. Expression of Bcl-2 and p53 genes was evaluated. Also, the cell cycle arrest and apoptotic effects were assessed. Results Hesp exerted anti-proliferative effects against HEp-2 cells which increase in time dependent manner. Gene profile analysis revealed highly significant decrease of anti-apoptotic Bcl-2 and highly significant increase of tumour suppressor gene P53 (p ˂ 0.01 and p ˂ 0.0001, respectively) for both tested drugs. Conclusion Hesp proved potential anticancer effects with reducing cancer cell viability in HEp-2 cell line via cell cycle arrest and apoptotic mechanism. It could be used as a pro-drug or co-adjuvant in treatment of oral cancer.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0